Cargando…

Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines

Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidel...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Alain, Scirè, Carlo Alberto, Talarico, Rosaria, Alexander, Tobias, Amoura, Zahir, Avcin, Tadej, Barsotti, Simone, Beretta, Lorenzo, Blagojevic, Jelena, Burmester, Gerd, Cavazzana, Ilaria, Cherrin, Patrick, Damian, Laura, Doria, Andrea, Fonseca, João Eurico, Furini, Federica, Galetti, Ilaria, Houssiau, Frederic, Krieg, Thomas, Larosa, Maddalena, Launay, David, Campanilho-Marques, Raquel, Martin, Thierry, Matucci-Cerinic, Marco, Moinzadeh, Pia, Montecucco, Carlomaurizio, Moraes-Fontes, Maria Francisca, Mouthon, Luc, Neri, Rossella, Paolino, Sabrina, Piette, Yves, Rednic, Simona, Tamirou, Farah, Tincani, Angela, Toplak, Natasa, Bombardieri, Stefano, Hachulla, Eric, Mueller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Vieira, Ana, Cutolo, Maurizio, Mosca, Marta, Cavagna, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397434/
https://www.ncbi.nlm.nih.gov/pubmed/30886730
http://dx.doi.org/10.1136/rmdopen-2018-000784
_version_ 1783399414552854528
author Meyer, Alain
Scirè, Carlo Alberto
Talarico, Rosaria
Alexander, Tobias
Amoura, Zahir
Avcin, Tadej
Barsotti, Simone
Beretta, Lorenzo
Blagojevic, Jelena
Burmester, Gerd
Cavazzana, Ilaria
Cherrin, Patrick
Damian, Laura
Doria, Andrea
Fonseca, João Eurico
Furini, Federica
Galetti, Ilaria
Houssiau, Frederic
Krieg, Thomas
Larosa, Maddalena
Launay, David
Campanilho-Marques, Raquel
Martin, Thierry
Matucci-Cerinic, Marco
Moinzadeh, Pia
Montecucco, Carlomaurizio
Moraes-Fontes, Maria Francisca
Mouthon, Luc
Neri, Rossella
Paolino, Sabrina
Piette, Yves
Rednic, Simona
Tamirou, Farah
Tincani, Angela
Toplak, Natasa
Bombardieri, Stefano
Hachulla, Eric
Mueller-Ladner, Ulf
Schneider, Matthias
Smith, Vanessa
Vieira, Ana
Cutolo, Maurizio
Mosca, Marta
Cavagna, Lorenzo
author_facet Meyer, Alain
Scirè, Carlo Alberto
Talarico, Rosaria
Alexander, Tobias
Amoura, Zahir
Avcin, Tadej
Barsotti, Simone
Beretta, Lorenzo
Blagojevic, Jelena
Burmester, Gerd
Cavazzana, Ilaria
Cherrin, Patrick
Damian, Laura
Doria, Andrea
Fonseca, João Eurico
Furini, Federica
Galetti, Ilaria
Houssiau, Frederic
Krieg, Thomas
Larosa, Maddalena
Launay, David
Campanilho-Marques, Raquel
Martin, Thierry
Matucci-Cerinic, Marco
Moinzadeh, Pia
Montecucco, Carlomaurizio
Moraes-Fontes, Maria Francisca
Mouthon, Luc
Neri, Rossella
Paolino, Sabrina
Piette, Yves
Rednic, Simona
Tamirou, Farah
Tincani, Angela
Toplak, Natasa
Bombardieri, Stefano
Hachulla, Eric
Mueller-Ladner, Ulf
Schneider, Matthias
Smith, Vanessa
Vieira, Ana
Cutolo, Maurizio
Mosca, Marta
Cavagna, Lorenzo
author_sort Meyer, Alain
collection PubMed
description Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients ’ and clinicians’ unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union’s Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients ’ preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations.
format Online
Article
Text
id pubmed-6397434
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-63974342019-03-18 Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines Meyer, Alain Scirè, Carlo Alberto Talarico, Rosaria Alexander, Tobias Amoura, Zahir Avcin, Tadej Barsotti, Simone Beretta, Lorenzo Blagojevic, Jelena Burmester, Gerd Cavazzana, Ilaria Cherrin, Patrick Damian, Laura Doria, Andrea Fonseca, João Eurico Furini, Federica Galetti, Ilaria Houssiau, Frederic Krieg, Thomas Larosa, Maddalena Launay, David Campanilho-Marques, Raquel Martin, Thierry Matucci-Cerinic, Marco Moinzadeh, Pia Montecucco, Carlomaurizio Moraes-Fontes, Maria Francisca Mouthon, Luc Neri, Rossella Paolino, Sabrina Piette, Yves Rednic, Simona Tamirou, Farah Tincani, Angela Toplak, Natasa Bombardieri, Stefano Hachulla, Eric Mueller-Ladner, Ulf Schneider, Matthias Smith, Vanessa Vieira, Ana Cutolo, Maurizio Mosca, Marta Cavagna, Lorenzo RMD Open Connective Tissue Diseases Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and inflammation, but in antisynthetase syndrome arthritis and interstitial lung disease are more frequent and often inaugurate the disease. Clinical practice guidelines (CPGs) have been proposed for IIMs, but they are sparse and heterogeneous. This work aimed at identifying: i) current available CPGs for IIMs, ii) patients ’ and clinicians’ unmet needs not covered by CPGs. It has been performed in the framework of the European Reference Network on rare and complex connective tissue and musculoskeletal diseases (ReCONNET), a network of centre of expertise and patients funded by the European Union’s Health Programme. Fourteen original CPGs were identified, notably recommending that: i) extra-muscular involvements should be assessed; ii) corticosteroids and methotrexate or azathioprine are first-line therapies of IIMs. ii) IVIG is a treatment of resistant-DM that may be also used in other resistant-IIMs; iii) physical therapy and sun protection (in DM patients) are part of the treatment; v) tumour screening for patients with DM include imaging of chest, abdomen, pelvis and breast (in woman) along with colonoscopy (in patients over 50 years); vi) disease activity and damages should be monitor using standardised and validated tools. Yet, only half of these CPGs were evidence-based. Crucial unmet needs were identified both by patients and clinicians. In particular, there was a lack of large multidisciplinary working group and of patients ’ preferences. The following fields were not or inappropriately targeted: diagnosis; management of extra-muscular involvements other than skin; co-morbidities and severe manifestations. BMJ Publishing Group 2019-02-26 /pmc/articles/PMC6397434/ /pubmed/30886730 http://dx.doi.org/10.1136/rmdopen-2018-000784 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Connective Tissue Diseases
Meyer, Alain
Scirè, Carlo Alberto
Talarico, Rosaria
Alexander, Tobias
Amoura, Zahir
Avcin, Tadej
Barsotti, Simone
Beretta, Lorenzo
Blagojevic, Jelena
Burmester, Gerd
Cavazzana, Ilaria
Cherrin, Patrick
Damian, Laura
Doria, Andrea
Fonseca, João Eurico
Furini, Federica
Galetti, Ilaria
Houssiau, Frederic
Krieg, Thomas
Larosa, Maddalena
Launay, David
Campanilho-Marques, Raquel
Martin, Thierry
Matucci-Cerinic, Marco
Moinzadeh, Pia
Montecucco, Carlomaurizio
Moraes-Fontes, Maria Francisca
Mouthon, Luc
Neri, Rossella
Paolino, Sabrina
Piette, Yves
Rednic, Simona
Tamirou, Farah
Tincani, Angela
Toplak, Natasa
Bombardieri, Stefano
Hachulla, Eric
Mueller-Ladner, Ulf
Schneider, Matthias
Smith, Vanessa
Vieira, Ana
Cutolo, Maurizio
Mosca, Marta
Cavagna, Lorenzo
Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
title Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
title_full Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
title_fullStr Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
title_full_unstemmed Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
title_short Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
title_sort idiopathic inflammatory myopathies: state of the art on clinical practice guidelines
topic Connective Tissue Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397434/
https://www.ncbi.nlm.nih.gov/pubmed/30886730
http://dx.doi.org/10.1136/rmdopen-2018-000784
work_keys_str_mv AT meyeralain idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT scirecarloalberto idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT talaricorosaria idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT alexandertobias idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT amourazahir idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT avcintadej idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT barsottisimone idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT berettalorenzo idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT blagojevicjelena idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT burmestergerd idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT cavazzanailaria idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT cherrinpatrick idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT damianlaura idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT doriaandrea idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT fonsecajoaoeurico idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT furinifederica idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT galettiilaria idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT houssiaufrederic idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT kriegthomas idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT larosamaddalena idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT launaydavid idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT campanilhomarquesraquel idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT martinthierry idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT matuccicerinicmarco idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT moinzadehpia idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT montecuccocarlomaurizio idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT moraesfontesmariafrancisca idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT mouthonluc idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT nerirossella idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT paolinosabrina idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT pietteyves idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT rednicsimona idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT tamiroufarah idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT tincaniangela idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT toplaknatasa idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT bombardieristefano idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT hachullaeric idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT muellerladnerulf idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT schneidermatthias idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT smithvanessa idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT vieiraana idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT cutolomaurizio idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT moscamarta idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines
AT cavagnalorenzo idiopathicinflammatorymyopathiesstateoftheartonclinicalpracticeguidelines